BB2-50F is a bactericidal inhibitor of M. tuberculosis with MIC value of 8 uM (H37Rv), inhibits succinate dehydrogenase (SDH) and the F1Fo-ATP synthase.
BB2-50F inhibits the growth of M. tuberculosis H37Rv and the BSL2 approved H37Rv auxotrophic-attenuated derivative mc2 6230 (ΔRD1, ΔpanCD) with MIC of 8 uM.
BB2-50F inhibits the growth of a panel of 22 M tuberculosis mc2 6206 (ΔleuD, ΔpanCD) mono-resistant mutants isolated against a variety of TB drugs including isoniazid (INH), rifampicin (RIF), BDQ, and PA-824 with a similar MIC as wild-type (WT).
BB2-50F (10X MIC) kills replicating cultures of M. tuberculosis mc2 6230 more rapidly than the current TB drugs BDQ, INH, and RIF.
BB2-50F potentiates the killing of M. tuberculosis by first- and second-line TB antibiotics.
BB2-50F inhibits mycobacterial succinate oxidation, dysregulates the TCA cycle and secretion of TCA cycle metabolites to prevent their intracellular toxicity.